Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is themed “The Art and Science of Cancer Care:
From Knowledge to Action” and is taking place in Chicago from May 30 to June 3, 202515.
Major data releases at this year’s meeting include advances in treating lung and breast cancers, the introduction of an AI tool to identify HER2 status, and evidence supporting the use of GLP-1 agonists to reduce cancer risks1.
Over 6,000 abstracts have been featured, with data likely to impact clinical practice across multiple cancer types1.
Advances highlighted by Institut Curie include a phase 3 study (SERENA-6) on intercepting treatment resistance in hormone-dependent metastatic breast cancer using liquid biopsies, ultra-sensitive circulating tumor DNA tests for triple-negative breast cancer, and new strategies for therapeutic de-escalation5.
There is growing interest in personalized medicine, including therapeutic vaccines for cancers such as HPV-associated diseases and metastatic pancreatic cancer, and highly effective targeted therapies for rare pediatric cancers5.
A notable focus of ASCO 2025 is the integration of big data and emerging technologies, with an emphasis on real-world evidence and artificial intelligence to enhance cancer care and patient outcomes1.
Advocacy and implementation efforts are being prioritized alongside scientific breakthroughs to ensure the latest research translates swiftly into improved care for cancer patients1.
Sources:
1. https://www.oncologynewscentral.com/oncology/first-studies-reported-ahead-of-2025-asco-annual-meeting